Regencell Bioscience Holdings Ltd (RGC) income statement
RGCNasdaqMedicinal Chemicals & Botanical Products
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Oct 7, 2026Score 5/30
$4.36−0.33 (-7.04%)
Close on Nov 19, 2026Market cap $2.16BP/E –Yield –
Regencell Bioscience Holdings Ltd income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2026
- -128.5%
Financial strength
- Current ratio
- 10.77
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 1074.6%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 161.96
- Dividend yield
- –
See a number that looks wrong?